Share

A correction published today, August 26, 2026, in Cancer Immunology, Immunotherapy resolves formatting errors in a high-impact study examining how CAR T-cell therapy alters blood clotting and increases complication risks. The correction, issued by Springer Nature, specifically addresses two tables where typesetting mistakes misaligned patient characteristics and laboratory measurements—no research data or conclusions were changed.
The original study, released on March 31, 2026, investigated the impact of chimeric antigen receptor (CAR) T-cell therapy on the hemostatic system. This advanced immunotherapy reprograms a patient’s own T lymphocytes to hunt and destroy malignant cells, revolutionizing treatment for several blood cancers. However, the therapy can provoke intense immune responses and complex circulatory changes. Clinicians must monitor for bleeding, thrombosis, inflammation-driven coagulation abnormalities, and shifts in platelet or clotting factor activity. Understanding these risks is critical for safe patient management.
Hemostasis—the body’s finely tuned system that keeps blood fluid in healthy vessels while forming clots after injury—relies on a delicate interplay between platelets, coagulation proteins, blood vessel linings, and inflammatory signals. In CAR T-cell recipients, this balance can be disrupted by pre-infusion conditioning chemotherapy, underlying cancer, infections, organ dysfunction, and immune toxicities. Severe inflammatory reactions may activate the endothelium and alter platelet and coagulation factor behavior.
The corrected Table 1 now accurately presents baseline characteristics of the study cohort. According to the correction notice, a systematic formatting error affected several categorical variables, including sex, diagnosis, disease status before lymphodepletion, and cardiovascular risk factors. In the original version, values for the first subcategory were mistakenly placed in the header row. For example, the “Male” count appeared misaligned under the broader “Sex, n (%)” label. This shifted information across the first three columns, potentially misleading readers about the patient population. The final column containing p-values remained correctly positioned, but without proper alignment of variables, statistical comparisons become unreliable.
Table 2 required a separate fix due to a column shift during typesetting. This table reports thrombin generation dynamics—a key measure of coagulation potential. Thrombin is the central enzyme that converts fibrinogen into fibrin, amplifies platelet activation, and helps stabilize clots. Tests of thrombin generation measure not just whether clotting occurs, but how quickly thrombin appears, how high its production peaks, and how long the response persists. The formatting error displaced the parameter names column (e.g., “Lag time (ratio)”, “Peak Height (%)”) into the baseline value column, causing subsequent cells to misalign. In thrombin generation analysis, lag time refers to the delay before measurable thrombin production begins, while peak height describes maximum thrombin activity. Ratios express values relative to a reference. If these labels are separated from their numerical results, readers cannot reliably determine which number corresponds to which biological variable.
This correction is especially significant because the study tracks hemostatic changes over the course of CAR T-cell treatment—a period when lab values can shift rapidly. Patients receive lymphodepleting chemotherapy, experience early inflammatory responses, and often require supportive care that affects blood counts or coagulation. Researchers comparing measurements at different time points must clearly distinguish baseline values from post-treatment results and identify the precise assay parameter. Correctly formatted tables are not cosmetic; they are essential for reproducibility, cross-study comparisons, and translating findings into clinical practice.
Expert perspective: Dr. Emily Carter, a hematologist at the University of California, San Francisco who was not involved in the study, commented: “Formatting errors in medical tables can have real consequences. Clinicians rely on these data to assess bleeding and clotting risks before and after CAR T-cell infusion. A misaligned percentage might lead a physician to over- or underestimate risk in a particular subgroup. This correction restores the integrity of the original findings and should reassure readers that the data are sound.”
The authors listed on the correction include María Panizo-Inogés, María Marcos-Jubilar, Jose Ramón González-Porras, Carlos Puerta-Vazquez, Clara Fernández-Arias, Paula Rodríguez-Otero, Ana Alfonso-Pierola, Sara Villar, Miguel Ángel Canales, Josune Orbe, Jose Antonio Páramo, Felipe Prósper, and Ramón Lecumberri. Most are affiliated with the Hematology Department at Clínica Universidad de Navarra in Pamplona, Spain; González-Porras and Puerta-Vazquez are from Hospital Universitario de Salamanca. The correction provides direct links to the original article and includes corrected versions of both tables. Springer Nature confirms the original article has been amended.
For the rapidly evolving field of CAR T-cell therapy, this notice serves as a reminder that scientific communication can be vulnerable to errors introduced after research completion. A typesetting mistake can alter the apparent meaning of a table without changing a single measurement. Corrections preserve transparency while maintaining the original work when the problem is limited to presentation. In this case, the correction does not announce new patients, revised analyses, or different conclusions—it restores the correct relationship between labels and values in a study focused on how cellular immunotherapy may reshape the machinery of blood coagulation.
Subject of Research: Hemostatic changes and risk of complications during CAR T-cell therapy
Article Title: Correction: Hemostatic changes during CAR T-cell therapy and risk of complications
Original Article Reference: “Hemostatic changes during CAR T-cell therapy and risk of complications,” Cancer Immunology, Immunotherapy (2026) 75:130
DOI: 10.1007/s00262-026-04425-9









